key: cord-0895615-wstaljwx
authors: Russo, Lilian Cristina; Tomasin, Rebeka; Matos, Isaac Araújo; Manucci, Antonio Carlos; Sowa, Sven T.; Dale, Katie; Caldecott, Keith W.; Lehtiö, Lari; Schechtman, Deborah; Meotti, Flavia C.; Bruni-Cardoso, Alexandre; Hoch, Nicolas Carlos
title: The SARS-CoV-2 Nsp3 macrodomain reverses PARP9/DTX3L-dependent ADP-ribosylation induced by interferon signalling
date: 2021-08-04
journal: J Biol Chem
DOI: 10.1016/j.jbc.2021.101041
sha: b6d58637cf0c3d75db54dc81504d0f51326c7dac
doc_id: 895615
cord_uid: wstaljwx

SARS-CoV-2 non-structural protein 3 (Nsp3) contains a macrodomain that is essential for coronavirus pathogenesis and is thus an attractive target for drug development. This macrodomain is thought to counteract the host interferon (IFN) response, an important antiviral signalling cascade, via the reversal of protein ADP-ribosylation, a post-translational modification catalysed by host poly(ADP-ribose) polymerases (PARPs). However, the main cellular targets of the coronavirus macrodomain that mediate this effect are currently unknown. Here, we use a robust immunofluorescence-based assay to show that activation of the IFN response induces ADP-ribosylation of host proteins and that ectopic expression of the SARS-CoV-2 Nsp3 macrodomain reverses this modification in human cells. We further demonstrate that this assay can be used to screen for on-target and cell-active macrodomain inhibitors. This IFN-induced ADP-ribosylation is dependent on PARP9 and its binding partner DTX3L, but surprisingly the expression of the Nsp3 macrodomain or the deletion of either PARP9 or DTX3L do not impair IFN signalling or the induction of IFN-responsive genes. Our results suggest that PARP9/DTX3L-dependent ADP-ribosylation is a downstream effector of the host IFN response and that the cellular function of the SARS-CoV-2 Nsp3 macrodomain is to hydrolyse this end product of IFN signalling, rather than to suppress the IFN response itself.

The SARS-CoV-2 pandemic has highlighted the need for an improved understanding of coronavirus pathogenesis for the development of novel antiviral strategies. The interferon (IFN) response is a central component of innate immunity and essentially precludes viral infection, as long as it is properly activated (1, 2) . Therefore, successful replication of a virus within host cells requires active suppression or evasion of the host IFN response, which is often mediated by multiple viral proteins acting via separate mechanisms (3) .

Type I IFN signalling is initiated upon recognition of viral nucleic acids in the cytoplasm, leading to the production and secretion of type I IFNs, such as IFNα and IFNβ, by virus-infected cells, whereas type II IFN, or IFNγ, is secreted by immune cells (1, 4) . Binding of these cytokines to transmembrane IFN receptors induces activation of JAK kinases such as TYK2, JAK1 and JAK2, leading to phosphorylation and nuclear translocation of transcription factors of the STAT family, mainly STAT1, and subsequent induction of several hundred interferon-stimulated genes (ISGs) (1, 2) .

Among these ISGs are several members of the poly(ADP-ribose) polymerase (PARP) family, which catalyse the post-translational modification of proteins with ADP-ribose units using NAD + as a substrate (5) .

ADP-ribosylation has recently emerged as a critical regulator of the IFN response, modulating central steps of this signalling cascade, both upstream of Type I IFN production and downstream of Type I or Type II IFN receptor binding (6) . Several IFN-regulated PARPs are also antiviral effectors, either by modifying host proteins involved in protein translation, stress granule formation and intracellular protein trafficking, or via modification and inhibition of viral proteins directly (6) . Interestingly, some of these IFN-responsive PARPs, including PARP9, are rapidly evolving in the primate lineage, suggesting that they are engaged in an "arms race" with viral pathogens (7) .

To counteract antiviral ADP-ribosylation by host PARPs, SARS-CoV-2 and other coronaviruses encode a macrodomain within non-structural protein 3 (Nsp3) that hydrolyses ADP-ribose modifications (8) (9) (10) . Importantly, inactivating mutations within this domain lead to reduced viral replication and increased activation of the host IFN response (11) (12) (13) , strongly indicating that pharmacological inhibition of the Nsp3 macrodomain may be of substantial therapeutic value (8, (14) (15) (16) .

Here, we show that activation of Type I or Type II IFN signalling induces ADP-ribosylation of host proteins that can be reversed by ectopic expression of the SARS-CoV-2 Nsp3 macrodomain in human cells. This ADP-ribosylation is dependent on the IFN-responsive PARP9/DTX3L heterodimer, but does not seem to modulate IFN signalling itself, since Nsp3 macrodomain expression or PARP9/DTX3L knockout had no effect on STAT1 phosphorylation or the induction of interferon-J o u r n a l P r e -p r o o f stimulated genes (ISGs). We propose that PARP9/DTX3L-dependent ADP-ribosylation of host proteins, which can be reversed by the SARS-CoV-2 Nsp3 macrodomain, is a downstream effector of the IFN response.

To study the functions of the SARS-CoV-2 Nsp3 macrodomain, we first engineered a sensitive assay to detect IFN-induced ADP-ribosylation in human cells. We transfected human A549 lung adenocarcinoma cells with the RNA mimetic poly(I:C), which induces a complete type I IFN cascade (17, 18) , or treated these cells with recombinant IFNγ, which induces type II IFN signalling (19, 20) .

As expected, both treatments led to robust phosphorylation of STAT1 on tyrosine Y701 (Fig. 1A) , which localized to the cell nucleus (Fig. 1B) . Using the Af1521 macrodomain-derived pan-ADPribose binding reagent (Millipore, MABE1016) for immunofluorescence staining and a high-content microscopy setup for robust image analysis and signal quantification (Sup. Fig. 1 and methods section), we observed a pronounced increase in a punctate, cytosolic ADP-ribose signal in response to either poly(I:C) or IFNγ treatment (Fig. 1C) . Therefore, both type I and type II IFN signalling induce detectable ADP-ribosylation in human cells.

Next, we generated A549 cell lines ectopically expressing FLAG-tagged SARS-CoV-2 Nsp3 macrodomain using lentiviral vectors and confirmed that nearly 100% of the cells express the macrodomain using anti-FLAG immunofluorescence staining ( Fig. 2A) . Strikingly, constitutive macrodomain expression substantially reduced both poly(I:C) or IFNγ -induced ADP-ribosylation compared to empty vector controls (Fig. 2B ). To confirm these results, we generated cells constitutively expressing a catalytically inactive N40A macrodomain mutant (9, 12) and repeated the experiment with the inclusion of recombinant IFNα and IFNβ. Again, expression of the WT macrodomain substantially reduced ADP-ribosylation induced by all of the treatments tested (Fig.2C ).

In contrast, expression of the N40A mutant had no appreciable effect on IFN-induced ADP-J o u r n a l P r e -p r o o f ribosylation (Fig. 2C) , indicating that catalytic activity was required for this effect. In these experiments, we observed that the N40A mutant was expressed at lower levels than the WT macrodomain (Sup. Fig. 2A ), which could, in principle, account for the higher persistence of ADPribose signal in the population of cells expressing the mutant protein. Therefore, the analysis in Fig.   2C includes only a subset of cells that express similar levels of WT and N40A macrodomain, based on anti-FLAG immunofluorescence intensity (Sup. Fig. 2B ), which did not alter the original result ( Fig. 2C and Sup. Fig. 2C-D) . To further strengthen these observations, we generated A549 cell lines with doxycycline-inducible expression of either WT or N40A mutant macrodomain (Sup. Fig. 2E ). As expected, IFNγ-induced ADP-ribosylation was indistinguishable between empty vector controls and either of the uninduced cells (Fig. 2D ). In agreement with the results above, doxycycline-induced expression of the WT macrodomain reduced ADP-ribosylation, which was once again restored by the N40A mutation (Fig. 2D ). As before, the cells used in this analysis were gated to ensure similar expression levels between WT and N40A mutant macrodomain, with no effect on the result (Sup. Fig.2F -G). Collectively, these data indicate that the Nsp3 macrodomain, when ectopically expressed in human cells, hydrolyses the ADP-ribosylation of host proteins induced by both type I or type II IFN signalling.

Given the urgent need for antiviral therapies for COVID-19 and the fact that the macrodomain is an attractive therapeutic target (8, (14) (15) (16) , we attempted to repurpose compounds that already have regulatory approval as potential Nsp3 macrodomain inhibitors. For this, we performed a structurebased virtual screen of a library of 6365 compounds that have been approved for human use by any regulatory agency in the world, against the deposited crystal structures of the SARS-CoV-2 Nsp3 macrodomain bound to ADP-ribose (PDB 6W02) ( Fig. 3A and methods) . Of the final list of 79 compounds of interest, 69 were sourced and tested in biochemical and cellular assays (Supplementary Table 1 ). Using thermal shift assays, which measure thermal stabilization of a protein upon ligand binding, we observed that, in contrast to the substantial shift in thermal stability of the Nsp3 macrodomain induced by the ADP-ribose positive control, none of the 69 test compounds showed any evidence of binding to the recombinant macrodomain (Fig. 3B) . Similar results were obtained in J o u r n a l P r e -p r o o f cellular assays, in which none of the compounds substantially restored IFN-induced ADP-ribosylation levels in macrodomain-expressing cells (Fig. 3C) , and the slight effect of atorvastatin observed in the cellular screen was not confirmed in follow-up experiments (Sup. Fig. 3 ).

Interestingly, we observed that some compounds reduced IFN-induced ADP-ribosylation (Fig. 3C) and one of these was tofacitinib, an inhibitor of the JAK kinases that phosphorylate STAT1 in response to IFN receptor activation (21) . As expected, tofacitinib treatment completely blocked STAT1-Y701 phosphorylation in response to IFNγ treatment (Fig. 4A, Sup.Fig. 4A ) and this resulted in a complete loss of IFN-induced ADP-ribosylation (Fig. 4B, Sup.Fig. 4A ). This suggests that ADPribosylation is likely to be catalysed by an IFN-responsive PARP that is transcriptionally induced by STAT1 complexes. This was corroborated by the fact that olaparib, an inhibitor of DNA-damage activated PARPs 1 and 2 that likely also inhibits PARP3, PARP4 and TNKS1/2 (PARP5a/b) at the relatively high concentration used here (22) (23) (24) , had no effect on IFN-induced ADP-ribosylation or on STAT1 phosphorylation ( Fig. 4A-B , Sup. Fig. 4A ).

One such IFN-responsive PARP is PARP9, which forms a heterodimer with DTX3L and has been shown to participate in IFN-mediated antiviral responses (25, 26) . We had previously generated PARP9 and DTX3L CRISPR knockout cells in an RPE1-hTERT background (methods section and Sup. Fig. 4B -C) and decided to test whether IFN-induced ADP-ribosylation was altered in these cells.

As with A549 cells, IFNγ treatment induced detectable ADP-ribosylation in RPE1 retinal pigment epithelial cells, confirming that this response is not specific to A549 cells (Fig.4C) . Surprisingly however, PARP9 KO and particularly DTX3L KO cells displayed severely reduced IFNγ-induced ADP-ribosylation compared to controls (Fig. 4C, Sup.Fig. 4D ). To determine if this was indirectly caused by an effect of PARP9 or DTX3L knockout on IFN signalling itself, we quantified STAT1-Y701 phosphorylation levels in response to IFNγ treatment in these cells, which revealed that PARP9 KO or DTX3L KO had no appreciable effect on STAT1 phosphorylation (Fig. 4D ). To ascertain if the Collectively, these data indicate that the Nsp3 macrodomain does not affect the host IFN signalling cascade or the induction of interferon-stimulated genes, but is instead involved in suppressing downstream biological processes triggered by IFN-induced ADP-ribosylation (Fig. 6 ).

Successful viral evasion or suppression of the host interferon response is key for the establishment of a viral infection and is often mediated by several viral factors acting on multiple host targets (3). The coronavirus Nsp3 macrodomain is thought to represent an important mediator of coronavirus pathogenesis by reversing host antiviral ADP-ribosylation and is thus an attractive drug target (8, (14) (15) (16) . However, little is known about the molecular targets of IFN-responsive PARPs and how reversal of these modifications by the Nsp3 macrodomain may exert its pro-viral effects.

We have established a cellular immunofluorescence-based assay that can detect the physiological levels of ADP-ribosylation induced by both type I and type II IFN signalling in response to the viral RNA mimetic poly(I:C) or recombinant interferon treatments ( Fig. 1 and 2) , which is consistent with previous studies showing that IFNγ treatment results in detectable ADP-ribosylation during the process of macrophage activation (31) . We demonstrated that ectopically expressed SARS-CoV-2

Nsp3 macrodomain can hydrolyse these modifications in human cells (Fig. 2) , which, to our knowledge, had so far only been shown in vitro using recombinant coronavirus Nsp3 macrodomains (9, 12) .

We have employed this assay in a repurposing screen for Nsp3 macrodomain inhibitors (Fig.3) , which turned out unsuccessful, but highlighted the reasonable throughput of our setup, which allowed two people to perform triplicate screens for 69 compounds in less than a week. Given the shortage of BSL-3 facilities required to test anti-coronavirus therapeutics on the SARS-CoV-2 virus directly, and the inherent uncertainty in these tests regarding on-target effects in case of successful reduction in viral loads (32), we believe that a cellular assay such as the one presented here may be a critical This microscopy-based assay also allowed us to investigate the origins and functions of the IFNinduced ADP-ribosylation. Interestingly, we observed that Nsp3 macrodomain expression was J o u r n a l P r e -p r o o f associated with a slight, but not statistically significant, reduction in ADP-ribosylation even in control cells ( Fig.2B-D) . As this effect was also observed upon tofacitinib treatment (Fig.4B) , this basal ADP-ribosylation signal may stem from low level endogenous IFN signalling in A549 cells.

Crucially, the signal we detected is predominantly cytosolic and has a punctate pattern (Fig. 1C) but, despite extensive efforts, we have so far been unsuccessful in co-localizing this signal with known cytosolic structures and organelles (LCR and NH, unpublished observations). Naturally, it will be critical to identify not only this structure but also the actual protein targets of the Nsp3 macrodomainsensitive ADP-ribosylation induced by the IFN response, in order to elucidate the putative antiviral function of this modification.

Given that inhibition of DNA damage-responsive PARPs with olaparib had no effect on IFN-induced ADP-ribosylation, but inhibition of JAK kinases completely prevented its formation ( Fig. 4A and B ), our data indicate that the ADP-ribosylation detected here is catalysed by a PARP whose expression is induced by IFN signalling. Importantly, we identified that the PARP9/DTX3L heterodimer, whose expression is IFN-stimulated (Fig. 5) , is absolutely necessary for this ADP-ribosylation, as the signal was lost upon knockout of either of these genes (Fig. 4) . Whether PARP9 or DTX3L are individually required for this activity is difficult to determine, as KO of either gene severely affected the stability of the binding partner (Sup. Fig. 4C ), in agreement with previous studies showing co-dependence of these proteins (25, 26) . Interestingly, PARP9 and DTX3L expression is also induced in cells infected with SARS-CoV-2, as long as viral load is high enough to induce an IFN response (33) . In agreement with our results, PARP9/DTX3L induction under these conditions is completely prevented by treatment with a JAK kinase inhibitor (33) . While it is tempting to speculate that PARP9/DTX3L directly catalyse the formation of the IFN-induced ADP-ribose signal we detected, we cannot rule out a role of these proteins in a putative signalling cascade that culminates in ADP-ribosylation by another PARP.

We propose that the PARP9/DTX3L heterodimer promotes this ADP-ribosylation as a downstream effector of the IFN response, as we did not observe an effect of PARP9/DTX3L deletion on STAT1 phosphorylation or ISG induction (Fig. 4) . These data are surprising, considering previous reports J o u r n a l P r e -p r o o f showing that PARP9 and DTX3L overexpression increases ISG induction in response to IFN signalling in human fibrosarcoma cells (26) and that PARP9 silencing reduces IFNγ-induced STAT1 phosphorylation and ISG induction in macrophages (34) . While further studies are clearly required to clarify the role of PARP9 and DTX3L in the IFN response, we speculate that differences in genetic manipulation of PARP9/DTX3L levels (overexpression, RNA interference or CRISPR/Cas9 KO) or cell types (fibrosarcoma, macrophage or retinal pigment epithelia) could account for these differences.

In agreement with our model for an effector function of this PARP9/DTX3L-dependent ADPribosylation, the ectopic expression of the Nsp3 macrodomain also had no effect on STAT1 phosphorylation or ISG induction (Fig. 5) , despite reversing PARP9/DTX3L-mediated ADPribosylation (Fig. 2) . This was again surprising, since macrodomain mutation in a mouse coronavirus model (mouse hepatitis virus-MHV) was previously shown to cause an increase in IFN production by virus-infected murine macrophages (13) . In this MHV model, the macrodomain was proposed to mainly counteract PARP14 activity (13) , which is thought to act upstream of the production of type I IFN by virus-infected cells (35) . These results are not necessarily conflicting, as our methodology may not detect the full complement of IFN-induced ADP-ribosylation or the MHV macrodomain may hydrolyse different PARP targets that play a more prominent role in the mouse IFN response relative to humans (36) . Alternatively, macrodomain mutation in the context of a full length Nsp3 protein may have secondary effects on the activity of other domains, such as the papain-like protease known to suppress IFN signalling (37, 38) .

In conclusion, we show here that the SARS-CoV-2 Nsp3 macrodomain hydrolyses PARP9/DTX3Ldependent ADP-ribosylation induced by IFN signalling and uncover a role for this modification as a putative effector, rather than modulator, of the IFN response (Fig. 6) . As part of this study, we developed a cellular assay with the potential to substantially impact drug discovery efforts currently underway to target the Nsp3 macrodomain as a novel anti-coronavirus therapy. 

The SARS-CoV-2 Nsp3 macrodomain (Uniprot identifier P0DTC1, residues 1024-1192) was cloned into pNH-TrxT vector (Addgene plasmid #26106) using SLIC restriction free cloning method (41) .

Briefly, the pNH-TrxT plasmid was linearized and 100 ng of linearized plasmid were mixed in a 1:4 molar ratio with SARS-CoV-2 Nsp3 macrodomain (gBlock gene fragment, Integrated DNA Technologies) and incubated with T4 DNA polymerase for 2.5 min at room temperature and for 10 min on ice. The mixture was used to transform NEB5α competent E. coli cells (New England BioLabs) according to manufacturer's instructions. Colonies were grown on LB agar containing 5% sucrose using the SacB-based negative selection marker (42) . . We subsequently discovered that these gRNAs, which were designed as tru-gRNAs with 17bp of homology plus a 5'G (43) are incompatible with the eSpCas9(1.1) mutant (44) . Therefore, RPE1-hTERT cells were co-transfected with either of these vectors and the hCas9 vector (Addgene #41815) using a Neon Transfection system (Thermo) and transfected cells selected with G418 for 5 days.

Individual clones were screened by western blotting and clones with complete absence of PARP9 and DTX3L protein were selected (Sup. Fig. 4B ). Genomic DNA surrounding the edited locus was amplified and analysed by Sanger sequencing (Sup. Fig. 4C ).

Adherent cells were washed in PBS and lysed directly in pre-heated Laemmli buffer devoid of bromophenol blue and beta-mercaptoethanol. Lysates were transferred to tubes, boiled for 15min and the protein concentration determined using BCA protein quantification kit (Pierce). After normalization of protein concentrations and addition of bromophenol blue and beta-mercaptoethanol, samples were boiled again for 10min and 15-50 µg of protein were loaded per sample in standard SDS-PAGE gels. Proteins were transferred to nitrocellulose membranes (Bio-Rad), visualized with Ponceau Red (Sigma) and the membranes cut horizontally such that different portions of the same membrane could be incubated with the appropriate antibodies. Membranes were blocked with 5% BSA for 30 min and incubated with primary antibody overnight at 4˚C. After extensive washing in TBST buffer, 1h incubation in appropriate HRP-conjugated secondary antibodies (Sigma) and another round of washing, membranes were incubated with ECL Prime (Amersham) and the signal detected using a Chemidoc MP Imaging System (Bio-Rad). Signals were quantified using ImageJ software. Fig. 1 ).

Total RNA was extracted from 10 6 cells using an RNAeasy kit (Qiagen), treated with DNAseI (Ambion) and reverse-transcribed using SuperScriptII (Thermo), according to manufacturer instructions, using both oligodT and random hexamer primers (Thermo). This cDNA was used for qPCR (5 ng/reaction) using Power SYBR green Master mix (Thermo) with three technical replicates per biological replicate, using 200 nM of the primer sets indicated in Table 1 , which were chosen from PrimerBank (45) . Reactions were performed on an Applied Biosystems 7500 Real-time PCR J o u r n a l P r e -p r o o f system, using default settings. RPL19 was used as housekeeping control and standard 2 -ΔΔCt analysis performed relative to the untreated control sample.

All experiments were repeated on at least three separate occasions, often with multiple parallel replicates processed on the same day, but treated as independently as possible. All graphs and statistical analyses were generated using GraphPad Prism software and display both the distributions of individual datapoints and their mean ± SEM of the normalized values relative to the IFNγ-treated control for each replicate, considered as 100%. Statistical comparisons between samples were performed using ANOVA, with p<0.0001 indicated by ****, p<0.001 indicated by *** and p<0.01 indicated by **.

All oligonucleotides and antibodies used in this study are presented in the tables below: 

The datasets generated during the current study are available from the corresponding author on reasonable request. 

Regulation of type I interferon responses

Interferon-Stimulated Genes: What Do They All Do?

Ten Strategies of Interferon Evasion by Viruses

The Dual Nature of Type I and Type II Interferons

ADP-ribosylation: from molecular mechanisms to human disease

The impact of PARPs and ADP-ribosylation on inflammation and host-pathogen interactions

Rapid evolution of PARP genes suggests a broad role for ADP-ribosylation in host-virus conflicts

The Viral Macrodomain Counters Host Antiviral ADP-Ribosylation

The SARS-CoV-2 Conserved Macrodomain Is a Mono-ADP-Ribosylhydrolase

Macrodomain ADP-ribosylhydrolase and the pathogenesis of infectious diseases

The nsp3 macrodomain promotes virulence in mice with coronavirus-induced encephalitis

The Conserved Coronavirus Macrodomain Promotes Virulence and Suppresses the Innate Immune Response during Severe Acute Respiratory Syndrome Coronavirus Infection

The coronavirus macrodomain is required to prevent PARP-mediated inhibition of virus replication and enhancement of IFN expression

Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors

Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes

TLR3: interferon induction by double-stranded RNA including poly(I:C)

Direct Antiviral Mechanisms of Interferon-Gamma

Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)

2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1

The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models

Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors

BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate

-DTX3L ubiquitin ligase targets host histone H2BJ and viral 3C protease to enhance interferon signaling and control viral infection

Induction of the transcription factor IRF-1 and interferon-beta mRNAs by cytokines and activators of second-messenger pathways

Genetically determined, interferon-dependent resistance to influenza virus in mice

Interferoninduced transcription of a gene encoding a 15-kDa protein depends on an upstream enhancer element

Interferon-dependent induction of mRNA activity for (2'-5')oligo-isoadenylate synthetase

A Study into the ADP-Ribosylome of IFN-gamma-Stimulated THP-1 Human Macrophage-like Cells Identifies ARTD8/PARP14 and ARTD9/PARP9 ADP-Ribosylation

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

and PARP14 crossregulate macrophage activation via STAT1 ADP-ribosylation

PARP14 Controls the Nuclear Accumulation of a Subset of Type I IFN-Inducible Proteins

Differences in innate immune response between man and mouse

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

Structure of the multiple functional domains from coronavirus nonstructural protein 3

Crystal structures of SARS-CoV-2 ADP-ribose phosphatase: from the apo form to ligand complexes

VMD: visual molecular dynamics

Onestep sequence-and ligation-independent cloning as a rapid and versatile cloning method for functional genomics studies

Direct selection for curing and deletion of Rhizobium plasmids using transposons carrying the Bacillus subtilis sacB gene

Improving CRISPR-Cas nuclease specificity using truncated guide RNAs

Rationally engineered Cas9 nucleases with improved specificity

PrimerBank: a PCR primer database for quantitative gene expression analysis

Engineering Af1521 improves ADP-ribose binding and identification of ADP-ribosylated proteins

Scale bars = 20 μm Figure 2 Ectopic expression of the Nsp3 macrodomain reverses IFN-induced ADP-ribosylation (A) Representative images of anti-FLAG immunofluorescence staining (green) and DAPI staining (blue) in A549 cells transduced either with an empty vector control (left) or with a lentiviral construct constitutively expressing FLAG-tagged SARS-CoV-2 Nsp3 macrodomain (right)

Quantification of ADP-ribose immunofluorescence signal intensity in A549 cells transduced either with empty vector control (e.v.) or with lentiviral constructs for constitutive expression of either WT macrodomain or catalytically dead N40A mutant

100 U/mL IFNγ, transfected with 0.1 µg/mL poly(I:C) or vehicle control. For µM of each of 69 test compounds (Sup. Table 1). Mean ± SEM (n=3)

Figure 4 IFN-inducible PARP9 and DTX3L are required for IFN-induced ADP-ribosylation (A) Quantification of nuclear STAT1 phospho-Y701 immunofluorescence signal intensity in A549 cells 24h after treatment with vehicle control or 100 U/mL IFNγ, with or without 10 µM tofacitinib or 10 µM olaparib, as indicated

with or without 10 µM tofacitinib or 10 µM olaparib, as indicated. Mean ± SEM

Quantification of ADP-ribose immunofluorescence signal intensity in WT

Representative image (top) and quantification (bottom) of immunoblot analyses for STAT1 phospho-Y701 and actin loading control in WT, PARP9 KO or DTX3L KO RPE1-hTERT cells 24h with either vehicle control, 100 U/mL IFN γ or transfection with 0.1 µg/mL poly(I:C)

Relative levels of mRNA for OAS1, IRF1, ISG15 and Mx1 genes determined by RT-qPCR in WT

U/mL IFNγ or transfection with 0.1 µg/mL poly(I:C), normalized to respective vehicle-treated WT cells

Quantification of nuclear STAT1 phospho-Y701 immunofluorescence signal intensity in A549 cells transduced either with empty vector control (e.v.) or with a lentiviral construct for constitutive expression of FLAG-tagged macrodomain, 24h after treatment with vehicle control, 100 U/mL IFNγ or transfection with 0.1 µg/ml poly(I:C). Mean ± SEM (n=14

Relative levels of mRNA for OAS1, IRF1, ISG15 and Mx1 genes determined by RT-qPCR in of FLAG-tagged macrodomain

U/mL IFNγ or transfection with 0.1 µg/ml poly(I:C), normalized to respective vehicle-treated empty vector control cells

The authors wish to thank Anthony Fehr (Univ. Kansas) for the macrodomain vector used for cloning and fruitful discussions; Michael Hottiger (Univ. Zurich) for an ADP-ribose-binding reagents; Heli Alanen (Univ. Oulu) for production of the recombinant SARS-CoV-2 macrodomain; Célia Braga 

The authors declare that they have no conflict of interest.J o u r n a l P r e -p r o o f